These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 9652912

  • 1. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK.
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [Abstract] [Full Text] [Related]

  • 2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 3. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN, Stock RG.
    Brachytherapy; 2003 Oct 01; 2(1):32-9. PubMed ID: 15062161
    [Abstract] [Full Text] [Related]

  • 4. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
    Gutman S, Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Adamovich E.
    BJU Int; 2006 Jan 01; 97(1):62-8. PubMed ID: 16336330
    [Abstract] [Full Text] [Related]

  • 5. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 6. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):981-7. PubMed ID: 15989998
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1367-82. PubMed ID: 15275722
    [Abstract] [Full Text] [Related]

  • 9. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
    Kollmeier MA, Stock RG, Cesaretti J, Stone NN.
    J Urol; 2005 Mar 01; 173(3):808-12. PubMed ID: 15711274
    [Abstract] [Full Text] [Related]

  • 10. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors.
    Steggerda MJ, van der Poel HG, Moonen LM.
    Radiother Oncol; 2008 Jul 01; 88(1):108-14. PubMed ID: 18039548
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
    Keyes M, Miller S, Moravan V, Pickles T, McKenzie M, Pai H, Liu M, Kwan W, Agranovich A, Spadinger I, Lapointe V, Halperin R, Morris WJ.
    Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1023-32. PubMed ID: 19111402
    [Abstract] [Full Text] [Related]

  • 12. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
    Williams SG, Millar JL, Duchesne GM, Dally MJ, Royce PL, Snow RM.
    Radiother Oncol; 2004 Oct 15; 73(1):33-8. PubMed ID: 15465143
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ, Nedelka MA, Arican ZL, Yamada Y, Cohen GN, Shippy AM, Park JJ, Zaider M.
    Brachytherapy; 2008 Oct 15; 7(1):1-6. PubMed ID: 18299108
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds.
    Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, Gould K.
    Radiother Oncol; 2007 Jan 15; 82(1):46-9. PubMed ID: 17161481
    [Abstract] [Full Text] [Related]

  • 20. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S, Cesaretti J, Stone NN, Stock RG.
    BJU Int; 2006 Nov 15; 98(5):979-81. PubMed ID: 17034599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.